SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 42840.
  • 2
    Scheja A, Hellmer G, Wollheim FA, Akesson A. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease. Br J Rheumatol 1993; 32: 5962.
  • 3
    Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 6826.
  • 4
    Varga J, Bashey RI. Regulation of connective tissue synthesis in systemic sclerosis [review]. Int Rev Immunol 1995; 12: 18799.
  • 5
    Gay S, Jones RE Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92: 3013.
  • 6
    Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol 2004; 41: 63143.
  • 7
    Okutani D, Lodyga M, Han B, Liu M. Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol 2006; 291: L12941.
  • 8
    Catarzi S, Biagioni C, Giannoni E, Favilli F, Marcucci T, Iantomasi T, et al. Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase. Biochim Biophys Acta 2005; 1745: 16675.
  • 9
    Kim HP, Kim TY, Lee MS, Jong HS, Kim TY, Lee JW, et al. TGF-β1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27(Kip1) CDK inhibitor in hepatoma cells replated on fibronectin. Biochim Biophys Acta 2005; 1743: 15161.
  • 10
    Mishra R, Zhu L, Eckert RL, Simonson MS. TGF-β-regulated collagen type I accumulation: role of Src-based signals. Am J Physiol Cell Physiol 2007; 292: C13619.
  • 11
    Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-β1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 2004; 279: 856776.
  • 12
    Atfi A, Drobetsky E, Boissonneault M, Chapdelaine A, Chevalier S. Transforming growth factor β down-regulates Src family protein tyrosine kinase signaling pathways. J Biol Chem 1994; 269: 3068893.
  • 13
    Manganini M, Maier JA. Transforming growth factor β2 inhibition of hepatocyte growth factor-induced endothelial proliferation and migration. Oncogene 2000; 19: 12433.
  • 14
    Vittal R, Horowitz JC, Moore BB, Zhang H, Martinez FJ, Toews GB, et al. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury. Am J Pathol 2005; 166: 36775.
  • 15
    Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, et al. Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003; 278: 123849.
  • 16
    Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias [published erratum appears in Expert Opin Investig Drugs 2007;16:1135]. Expert Opin Investig Drugs 2007; 16: 67987.
  • 17
    Distler JH, Hagen C, Hirth A, Muller-Ladner U, Lorenz HM, del Rosso A, et al. Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-κB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol 2004; 65: 38999.
  • 18
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 19
    Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 2000; 20: 901827.
  • 20
    Tian G, Cory M, Smith AA, Knight WB. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry 2001; 40: 708491.
  • 21
    Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52: 85664.
  • 22
    Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 10916.
  • 23
    Bergman M, Joukov V, Virtanen I, Alitalo K. Overexpressed Csk tyrosine kinase is localized in focal adhesions, causes reorganization of αvβ5 integrin, and interferes with HeLa cell spreading. Mol Cell Biol 1995; 15: 71122.
  • 24
    Ishizawar RC, Tice DA, Karaoli T, Parsons SJ. The C terminus of c-Src inhibits breast tumor cell growth by a kinase-independent mechanism. J Biol Chem 2004; 279: 2377381.
  • 25
    Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF III, Gay RE, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A 2005; 102: 28927.
  • 26
    Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006; 54: 21425.
  • 27
    Distler JH, Huber LC, Hueber AJ, Reich CF III, Gay S, Distler O, et al. The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis 2005; 10: 73141.
  • 28
    Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 31122.
  • 29
    Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 45662.
  • 30
    Severgnini M, Takahashi S, Tu P, Perides G, Homer RJ, Jhung JW, et al. Inhibition of the Src and Jak kinases protects against lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med 2005; 171: 85867.
  • 31
    Chen KC, Zhou Y, Zhang W, Lou MF. Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells. Mol Vis 2007; 13: 37487.
  • 32
    Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib [review]. Nat Rev Drug Discov 2006; 5: 7178.
  • 33
    Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201: 92535.
  • 34
    Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 130816.
  • 35
    Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 111.
  • 36
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 253141.
  • 37
    Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, et al. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004; 113: 88594.